Clinical Trials

NCT07006805 | WITHDRAWN | PHASE1/PHASE2
0 participants

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-25
Start Date:
2026-06-30
Completion:
2028-09-30
Conditions
  • Relapsing Multiple Sclerosis (RMS)
  • Progressive Multiple Sclerosis (PMS)
  • Multiple Sclerosis - Relapsing Remitting
  • Multiple Sclerosis
  • Multiple Sclerosis (Relapsing Remitting)
  • Multiple Sclerosis (MS) - Relapsing-remitting
  • Progressive Multiple Sclerosis
Interventions
  • BIOLOGICAL
No Results Yet
NCT06891443 | RECRUITING | PHASE3
32 participants

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-25
Start Date:
2025-06-04
Completion:
2027-11-30
Conditions
  • Leber Congenital Amaurosis 10
  • Blindness
  • Leber Congenital Amaurosis
  • Sensation Disorders
  • Vision Disorder
  • Neurological Manifestations
  • Eye Diseases, Hereditary
  • Eye Diseases
  • Eye Disorders Congenital
  • Retinal Disease
Interventions
  • DRUG
  • OTHER
No Results Yet
NCT06790706 | ACTIVE_NOT_RECRUITING | PHASE2
27 participants

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Study Type:
INTERVENTIONAL
Last Updated:
2026-06-25
Start Date:
2025-10-01
Completion:
2028-11-30
Conditions
  • Peritoneal Mesothelioma
  • Gestational Trophoblastic Tumor
  • Anaplastic Thyroid Carcinomas
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Carcinoid Tumor
  • Thymic Carcinoma
Interventions
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page